Untangling exactly whom lecanemab is FDA-approved for

Elsewhere on this website (see Related Pages below), we noted that: – In 2021 and 2023, the United States Food and Drug Administration (FDA) announced the approval of two treatments for Alzheimer’s disease that were qualitatively different from those that have been available so far because they are “disease-modifying treatments”: Aducanumab (brand name Aduhelm®). But, on January…